Objective: Most type 2 diabetes mellitus patients are obese and have obesity related vascular complications. Sodium glucose cotransport-2 inhibitor (SGLT-2 inh) treatment is well known for both decreasing glycated hemoglobin levels and reduction in body weight. So, this study aimed to determine the effects of SGLT-2 inh on body composition, glycated hemoglobin levels, and vascular stiffness in obese type 2 diabetes mellitus patients. Methods: For 6 month, 60 obese type 2 diabetes mellitus patients were administered 10 mg once daily. Patients’ height, body weight, glycated hemoglobin levels, lipid profile, pulse wave velocity (PWV), body mass index, fat mass, and muscle mass were measured by using Inbody at baseline and after 6 months of treatment. Results: After 6 months of treatment, glycated hemoglobin levels decreased significantly (P = 0.021). Triglyceride levels decreased (0.001), while high density lipoprotein levels increased (0.025). Body weight (3.6 kg), and fat mass (2.6 kg) decreased significantly (P < 0.001 and P < 0.001, respectively), while interestingly, muscle mass did not decrease (P = 0.190). In addition to, Waist-to-hip ratio tend to decreased but not significantly, and aortic PWV decreased (P = 0.051). Conclusion: Effects of 6 months follow up SGLT-2 inh use in obese type 2 diabetes mellitus with cardiometabolic high risk patients not only reduced body weight without muscle mass loss, body fat mass, and glycated hemoglobin levels but also improved aortic PWV in accordance with dyslipidemia.